KLF17 mainly acts on the promoters of epithelial mesenchymal transition-related genes such as id-1, E-cadherin, ZO-1, vimentin and fibronectin to inhibit them.34 Studies in metastatic breast cancer cells drew the conclusion that by either directly or indirectly binding to the promoter of KLF17, mutant p53-R282W decreases the metastasis suppressor function of KLF17 in these cell lines to facilitate cancer progression.35 Similar results can be observed in other mutants such as R175H-, R273H- and R280K-induced breast cancer cell lines (Figure 3). Here, TJP1 is linked to breast cancer.